Falcon's Beyond Global, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Falcon's Beyond Global, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.90M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.75M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $18.24M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $15.95M | Apr 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.41M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($15.87M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($57.16M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($17.34M) | Apr 29, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $179.0K | Apr 3, 2025 |
| FY2024 | Dec 31, 2023 | $1.25M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $2.77M | Apr 29, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.50M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $22.41M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $28.06M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $18.44M | Apr 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.60M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($12.55M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($23.42M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($19.29M) | Apr 29, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $11.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $308.0K | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $320.0K | Apr 29, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.70M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $61.23M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $63.36M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $112.27M | Apr 29, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.88M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $81.33M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $552.35M | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $43.91M | Apr 29, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.93M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($8.97M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($57.11M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $68.36M | Apr 29, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $11.47M | Apr 29, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($44.24M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($46.54M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($68.60M) | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | ($24.15M) | Apr 29, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.87M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $825.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $672.0K | Apr 3, 2025 |
| FY2023 | Dec 31, 2022 | $8.37M | Apr 29, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.62M | Mar 30, 2026 |
| FY2024 | Dec 31, 2024 | $41.21M | Apr 3, 2025 |
| FY2023 | Dec 31, 2023 | $29.62M | Apr 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 30, 2026 |
| FY2023 | Dec 31, 2023 | (6) | Apr 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Apr 3, 2025 |